| Literature DB >> 32765023 |
Joyce S Ramos1,2, Lance C Dalleck2,3, Rebecca C Stennett1, Gregore I Mielke1, Shelley E Keating1, Lydia Murray4, Sumaira Z Hasnain4,5, Robert G Fassett1, Michael McGuckin4,6, Ilaria Croci1,7, Jeff S Coombes1.
Abstract
INTRODUCTION: IL-22 may have a role in the alleviation of the metabolic syndrome (MetS) via protection of pancreatic beta and endothelial cells from oxidative and lipid-induced damage. We aimed to investigate the effects of moderate-intensity continuous training (MICT) and different volumes of high-intensity interval training (HIIT) on changes in circulating IL-22.Entities:
Keywords: IL-22; cardiovascular disease; cytokine; high-intensity interval training; inflammation; metabolic syndrome
Year: 2020 PMID: 32765023 PMCID: PMC7368330 DOI: 10.2147/DMSO.S251567
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.168
Figure 1Flowchart for IL-22 sub-study. MICT, moderate-intensity continuous training; 4HIIT, 4 X 4 min high-intensity interval training; 1 x 4 min high-intensity interval training.
Figure 2Schematic representation of MICT (A), 4HIIT (B) and 1HIIT (C).
Participants’ Characteristics
| Variables | MICT (n=10) | 4HIIT (n=13) | 1HIIT (n=16) | P-value |
|---|---|---|---|---|
| Age, years, mean ± SD | 54 ± 9 | 54 ± 10 | 57 ± 8 | 0.47 |
| Male sex, % | 50 | 69 | 69 | 0.56 |
| Type 2 diabetes, % | 20 | 62 | 56 | 0.10 |
| Hypertension, % | 60 | 85 | 75 | 0.41 |
| ACEIs, % | 30 | 46 | 56 | 0.43 |
| Calcium Antagonist, % | 0 | 23 | 13 | 0.26 |
| Beta-blocker, % | 20 | 0 | 19 | 0.24 |
| Statin, % | 20 | 46 | 63 | 0.11 |
| Aspirin, % | 20 | 23 | 19 | 0.96 |
| Metformin,% | 10 | 38 | 38 | 0.26 |
Abbreviations: MICT, moderate-intensity continuous training; 4HIIT, 4xX4min high-intensity interval training; 1HIIT, 1X4min high-intensity interval training; ACEIs, angiotensin-converting enzyme inhibitors.
Changes in Metabolic Syndrome Severity, Fitness, Fatness, and Other Cardiometabolic Parameters Following Different Types of Training in All Participants
| MICT (n=10) | Effect Size Within Group | 4HIIT (n=13) | Effect Size Within Group | 1HIIT (n=16) | Effect Size Within Group | Group Difference | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change | Cohen’s | Baseline | Change | Cohen’s | Baseline | Change | Cohen’s | η2 Adjusted for Baseline Value | |||
| IL-22, pg/mL | 28.9 (10.4 to 44.4) | −17% (−43 to 31.3) | 0.15 | 23.1 (8.8 to 45.2) | 16.5% (−18.9 to 154.9) | 0.30 | 29.8 (13.9 to 152.9) | 15.9% (−28.7 to 46.1) | 0.02 | 0.14 | 0.14 | |
| HsCRP, mg/l | 1.8 (0.8 to 3.1) | −33% (−43 to −4.7) | 0.38 | 1.4 (0.9 to 2.8) | 24% (−12 to 124) | 0.28 | 1.8 (0.6 to 1.9) | 3% (−94 to 5) | 0.07 | 0.24 | 0.07 | |
| Metabolic syndrome z-score | 1.8 | −0.5±1.8 | 0.22 | 2.7 | −0.5±0.9 | 0.22 | 2.4 | −1.3±1.8 | 0.40 | 0.31 | 0.06 | |
| Triglycerides, mmol.l−1 | 1.5 (1.3 to 1.8) | 0.03 (−0.4 to 0.4) | 0.03 | 2.2±0.8 | 0.03±0.7 | 0.03 | 1.8±0.8 | −0.2±0.6 | 0.23 | 0.82 | 0.01 | |
| HDL-C, mmol.l−1 | 1.3±0.3 | 0.03±0.3 | 0.09 | 1.00 (0.9 to 1.1) | −0.01 (−0.2 to 0.03) | 0.17 | 1.1±0.4 | 0.2±0.2 | 0.44 | 0.03 | 0.17 | |
| Fasting glucose, mmol.l−1 | 5.7 (5.3 to 6.5) | −0.2 (−0.8 to 0.4) | 0.10 | 6.3 (5.2 to 8.0) | −0.05 (−0.6 to 0.4) | 0.06 | 6.5 (5.3 to 7.9) | −0.46 (−0.62 to 0.71) | 0.16 | 0.82 | 0.01 | |
| Waist circumference, cm | 108±15 | −1±5 | 0.06 | 106±12 | −2±5 | 0.17 | 102±13 | −2±4 | 0.15 | 0.73 | 0.02 | |
| Systolic blood pressure, mmHg | 130±13 | −5±9 | 0.32 | 126±10 | 1±10 | 0.20 | 137±13 | −9±9 | 0.62 | 0.21 | 0.06 | |
| Diastolic blood pressure, mmHg | 86±10 | −4±6 | 0.40 | 83±8 | −5±7 | 0.67 | 84±9 | −5 (−9 to 1) | 0.44 | 0.74 | 0.01 | |
| HOMA-IR | 6.9±4.9 | −2.1±2.7 | 0.51 | 5.9±1.9 | −0.8±1.4 | 0.51 | 5.2 (3.7 to 6.8) | −1.2 (−1.6 to 0.7) | 0.32 | 0.41 | 0.05 | |
| Absolute V̇O2peak, l.min−1 | 2.3 | 0.3±0.2 | 0.40 | 2.4 | 0.5±0.4 | 0.46 | 2.3 | 0.2±0.2 | 0.43 | 0.16 | 0.10 | |
| Relative V̇O2peak, mL.kg−1.min−1 | 23.2 | 2.7±1.9 | 0.42 | 23.2 | 5.7±4.7 | 0.82 | 26.2 | 2.9±2.2 | 0.38 | 0.03 | 0.18 | |
| Visceral adipose tissue, g | 1159.2±316.8 | −47.2±152.6 | 0.15 | 1154.5±404.2 | −68.2±106.0 | 0.39 | 1037.9±338.7 | −44.9±102.7 | 0.13 | 0.84 | 0.01 | |
| Total body fat, % | 43.4±8.4 | −0.3±1.9 | 0.02 | 40.5±6.7 | −1.2±1.8 | 0.18 | 38.1±7.5 | −0.8±1.5 | 0.11 | 0.36 | 0.06 | |
| Android fat, % | 48.7±7.3 | −0.2±2.3 | 0.03 | 46.7±5.3 | −1.4±2.3 | 0.26 | 44.1±5.3 | −1.4±2.7 | 0.28 | 0.23 | 0.08 | |
| Gynoid fat, % | 42.2±9.8 | −0.3±1.6 | 0.03 | 39.2±7.0 | −0.8±2.0 | 0.11 | 36.1±8.5 | −0.4±1.5 | 0.05 | 0.72 | 0.02 | |
| Lean Mass, kg | 54.2±13.3 | −0.2±2.2 | 0.02 | 56.3±10.6 | 0.04±1.8 | <0.01 | 53.3±11.9 | −0.1±1.2 | <0.01 | 0.93 | <0.001 | |
| Weight, kg | 100.7±21.9 | −0.4±4.5 | 0.01 | 100.6±19 | −2.7±5.9 | 0.16 | 92.1±21.7 | −2.3±3.9 | 0.11 | 0.37 | 0.05 | |
| Body mass index, kg.m2 −1 | 34±6.5 | −0.2±1.5 | 0.03 | 30.6 (29.7 to 35.6) | −0.6 (−1.3 to 0.3) | 0.28 | 30.8±6.1 | −0.1±2.9 | 0.03 | 0.80 | 0.01 | |
Abbreviations: ANCOVA, analysis of covariance; MICT, moderate-intensity continuous training; 4HIIT, 4X4min high-intensity interval training; 1HIIT, 1X4min high-intensity interval training. Variables are reported as mean change ± SD or percent/absolute median change (IQR).